Study to Establish the Diagnostic Performance of 18F Fluciclovine PET in Detecting Recurrent Brain Metastases
A phase 3 trial of Fluciclovine F-18 in Brain metastases, run by Blue Earth Diagnostics, completed.
Overview
Study to Establish the Diagnostic Performance of 18F Fluciclovine PET in Detecting Recurrent Brain Metastases is a phase 3 interventional study registered as NCT04410133 by Blue Earth Diagnostics, with 151 participants recorded, started 2020-10-26 and reaching its primary completion in 2023-06-05. Interventions recorded: 18F fluciclovine. Conditions recorded: Brain Metastases.
Linked to the drug Fluciclovine F-18 because the registry names it among its interventions and Brain metastases among its conditions. Registry record only: no result has been read by an editor.
Similar pages
not linked directly; found by shared links- Trial18F-Fluciclovine PET Imaging for Detecting High Grade Glioma Recurrence After Radiochemotherapy
Shares Fluciclovine F-18 and the tag pipeline.
- Trial[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
Shares Blue Earth Diagnostics (Bracco) and the tag pipeline.
- Trial[68Ga]BED003 PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
Shares Blue Earth Diagnostics (Bracco) and the tag pipeline.
- TrialPhase II Study of Gamma Knife Radiosurgery and Temozolomide for Brain Metastases
Shares Brain metastases (secondary brain tumours) and the tag pipeline.
- TrialTreating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
Shares Fluciclovine F-18 and the tag pipeline.
- TrialPhase 2b Imaging Study of RAD101 in Participants With Suspected Recurrent Brain Metastases
Shares Brain metastases (secondary brain tumours) and the tag pipeline.
- TrialEfficacy and Safety of SPH4336 in Combination With Endocrine Therapy in Breast Cancer Patients With Brain Metastases.
Shares Brain metastases (secondary brain tumours) and the tag pipeline.
- TrialA Pivotal Phase II Clinical Trial of Utidelone Injection Plus Capecitabine in HER2-negative Breast Cancer Patients With Brain Metastases
Shares Brain metastases (secondary brain tumours) and the tag pipeline.